ELI LILLY AND COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ELI LILLY AND COMPANY (LLY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 0.36% for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-21.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2013-02-21
- ELI LILLY AND COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2012 was 0.36%, a 73.53% decline from fiscal 2011.
- ELI LILLY AND COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2011 was 1.36%, a 0.00% change from fiscal 2010.
- ELI LILLY AND COMPANY share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2010 was 1.36%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2012-12-31 | 0.36% 10-K · filed 2013-02-21 |
| 2011-12-31 | 1.36% 10-K · filed 2013-02-21 |
| 2010-12-31 | 1.36% 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |